{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:07:56Z","timestamp":1747156076495,"version":"3.40.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bbrep.2024.101724","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:15:28Z","timestamp":1714731328000},"page":"101724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Utility of pemafibrate in nonalcoholic steatohepatitis model mice induced by a choline-deficient, high-fat diet and dextran sulfate sodium"],"prefix":"10.1016","volume":"38","author":[{"given":"Takahiro","family":"Ota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Soga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuki","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5595-2330","authenticated-orcid":false,"given":"Masaya","family":"Tamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrep.2024.101724_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrep.2024.101724_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12072-021-10143-4","article-title":"The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040","volume":"15","author":"Ito","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.bbrep.2024.101724_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrep.2024.101724_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163069","article-title":"Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression: an observational study in patients with nonalcoholic fatty liver disease","volume":"11","author":"Pelusi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrep.2024.101724_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrep.2024.101724_bib6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","article-title":"Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma","volume":"126","author":"El-Serag","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrep.2024.101724_bib7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13098-023-01187-7","article-title":"Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage","volume":"15","author":"Nomoto","year":"2023","journal-title":"Diabetol. Metab. Syndrome"},{"key":"10.1016\/j.bbrep.2024.101724_bib8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol. Therapeut."},{"key":"10.1016\/j.bbrep.2024.101724_bib9","doi-asserted-by":"crossref","first-page":"G483","DOI":"10.1152\/ajpgi.00079.2013","article-title":"Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment","volume":"305","author":"Clapper","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrep.2024.101724_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","article-title":"A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma","volume":"46","author":"Fujii","year":"2013","journal-title":"Med. Mol. Morphol."},{"key":"10.1016\/j.bbrep.2024.101724_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrep.2024.101724_bib12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrep.2024.101724_bib13","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrep.2024.101724_bib14","article-title":"Utility of ultrasonography in a mouse model of non-alcoholic steatohepatitis induced by a choline-deficient, high-fat diet and dextran sulfate sodium","volume":"36","author":"Hayakawa","year":"2023","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.bbrep.2024.101724_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040720","article-title":"Selective PPAR\u03b1 modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis","volume":"11","author":"Murakami","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bbrep.2024.101724_bib16","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41598-022-06542-8","article-title":"Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy","volume":"12","author":"Kanno","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrep.2024.101724_bib17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/gut.2009.197822","article-title":"Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome","volume":"59","author":"Bauer","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.bbrep.2024.101724_bib18","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.bbrep.2024.101724_bib19","first-page":"459","article-title":"Histological and immunohistochemical assessment of liver biopsies in morbidly obese patients","volume":"27","author":"Caballero","year":"2012","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.bbrep.2024.101724_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jhep.2008.12.016","article-title":"Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH","volume":"50","author":"Caballero","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrep.2024.101724_bib21","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2005.06.061","article-title":"CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation","volume":"129","author":"Obermeier","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrep.2024.101724_bib22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/0016-5085(90)90290-H","article-title":"A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice","volume":"98","author":"Okayasu","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrep.2024.101724_bib23","doi-asserted-by":"crossref","first-page":"G1328","DOI":"10.1152\/ajpgi.00467.2004","article-title":"Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL\/6 but not in BALB\/c mice: correlation between symptoms and inflammation","volume":"288","author":"Melgar","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrep.2024.101724_bib24","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/gut.2007.147595","article-title":"Reduced mucin sulfonation and impaired intestinal barrier function in the hyposulfataemic NaS1 null mouse","volume":"58","author":"Dawson","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.bbrep.2024.101724_bib25","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jhep.2011.02.035","article-title":"DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH","volume":"55","author":"G\u00e4bele","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrep.2024.101724_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bbrc.2015.12.012","article-title":"DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model","volume":"470","author":"Achiwa","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrep.2024.101724_bib27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.14218\/JCTH.2021.00315","article-title":"Premorbid steatohepatitis increases the seriousness of dextran sulfate sodium-induced ulcerative colitis in mice","volume":"10","author":"Wang","year":"2022","journal-title":"J. Clinic. Translat. Hepatol."},{"key":"10.1016\/j.bbrep.2024.101724_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bbrep.2024.101724_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrep.2024.101724_bib30","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrep.2024.101724_bib31","doi-asserted-by":"crossref","first-page":"G564","DOI":"10.1152\/ajpgi.00153.2014","article-title":"PPAR\u03b1-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate","volume":"307","author":"Qi","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrep.2024.101724_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/nu15224813","article-title":"Sea cucumber peptides ameliorate DSS-induced ulcerative colitis: the role of the gut microbiota, the intestinal barrier, and macrophage polarization","volume":"15","author":"Yu","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.bbrep.2024.101724_bib33","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1080\/13880209.2023.2233565","article-title":"Transcriptomic analysis reveals the regulatory mechanism underlying the indirubin-mediated amelioration of dextran sulfate sodium-induced colitis in mice","volume":"61","author":"Liu","year":"2023","journal-title":"Pharmaceut. Biol."},{"key":"10.1016\/j.bbrep.2024.101724_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176122","article-title":"IGF2\/IGF2R\/Sting signaling as a therapeutic target in DSS-induced ulcerative colitis","volume":"960","author":"Chen","year":"2023","journal-title":"Eur. J. Pharmacol."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580824000888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580824000888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T22:03:05Z","timestamp":1719007385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580824000888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"alternative-id":["S2405580824000888"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2024.101724","relation":{},"ISSN":["2405-5808"],"issn-type":[{"type":"print","value":"2405-5808"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of pemafibrate in nonalcoholic steatohepatitis model mice induced by a choline-deficient, high-fat diet and dextran sulfate sodium","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2024.101724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101724"}}